Olanzapine may increase the QTc-prolonging activities of Disopyramide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ramelteon. The risk or severity of adverse effects can be increased when Olanzapine is combined with Etorphine. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dimenhydrinate. The risk or severity of adverse effects can be increased when Olanzapine is combined with Maprotiline. The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Brexpiprazole. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tiapride. The serum concentration of Nelfinavir can be decreased when it is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Darifenacin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Melatonin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ezogabine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Methapyrilene. The risk or severity of adverse effects can be increased when Olanzapine is combined with Gabapentin. The therapeutic efficacy of Glyburide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Ergonovine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Triprolidine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pentazocine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cetirizine. The risk or severity of adverse effects can be increased when Bromazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Camazepam is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Toremifene. Olanzapine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ziconotide. Olanzapine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Halazepam. The metabolism of Olanzapine can be decreased when combined with Zucapsaicin. The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Trichloroethylene. The serum concentration of Olanzapine can be decreased when it is combined with Cyproterone acetate. The risk or severity of adverse effects can be increased when Olanzapine is combined with Isoflurane. Olanzapine may increase the QTc-prolonging activities of Pimozide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Opium. The therapeutic efficacy of Quinagolide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Zaleplon. The serum concentration of Olanzapine can be decreased when it is combined with Peginterferon alfa-2b. The therapeutic efficacy of Levodopa can be decreased when used in combination with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Desipramine. The serum concentration of Atazanavir can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Rizatriptan is combined with Olanzapine. The risk or severity of adverse effects can be increased when Quazepam is combined with Olanzapine. Olanzapine may decrease the stimulatory activities of MMDA. Olanzapine may increase the QTc-prolonging activities of Bedaquiline. The risk or severity of adverse effects can be increased when Olanzapine is combined with Eszopiclone. Olanzapine may increase the QTc-prolonging activities of Clozapine. Olanzapine may increase the QTc-prolonging activities of Artemether. Iproniazid may increase the serotonergic activities of Olanzapine. Indalpine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levorphanol. The metabolism of Olanzapine can be decreased when combined with Midostaurin. Olanzapine can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects. The metabolism of Olanzapine can be decreased when combined with Rolapitant. The risk or severity of adverse effects can be increased when Frovatriptan is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Flunarizine. Olanzapine may increase the QTc-prolonging activities of Sulfisoxazole. The risk or severity of adverse effects can be increased when Olanzapine is combined with Molindone. The therapeutic efficacy of Olanzapine can be increased when used in combination with Pregabalin. The risk or severity of adverse effects can be increased when Propericiazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Etomidate. Harmaline may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Oxybuprocaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Gepirone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl chloride. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ritanserin. The therapeutic efficacy of Pramlintide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Lisuride is combined with Olanzapine. Nefazodone may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Trimipramine. The risk or severity of adverse effects can be increased when Rasagiline is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Caffeine. The risk or severity of adverse effects can be increased when Naratriptan is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ketobemidone. The risk or severity of adverse effects can be increased when Temazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Thioproperazine is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Flecainide. The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Alimemazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Oxethazaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Benzocaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ecopipam. Olanzapine may increase the QTc-prolonging activities of Asenapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ropivacaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Primidone. The metabolism of Olanzapine can be decreased when combined with Cocaine. Olanzapine may increase the QTc-prolonging activities of Methadone. The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Linezolid is combined with Olanzapine. The therapeutic efficacy of Voglibose can be decreased when used in combination with Olanzapine. The serum concentration of Ledipasvir can be decreased when it is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Cimetidine. Olanzapine may increase the QTc-prolonging activities of Cisapride. Olanzapine may increase the QTc-prolonging activities of Iloperidone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Phenoxyethanol. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pethidine. Octamoxin may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethosuximide. Olanzapine may decrease the stimulatory activities of Midomafetamine. The risk or severity of adverse effects can be increased when Perazine is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Citalopram. The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Rufinamide is combined with Olanzapine. The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Lenvatinib. The metabolism of Olanzapine can be decreased when combined with Clobazam. The metabolism of Olanzapine can be decreased when combined with Isoniazid. The risk or severity of adverse effects can be increased when BL-1020 is combined with Olanzapine. The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Olanzapine. The therapeutic efficacy of Repaglinide can be decreased when used in combination with Olanzapine. Dapoxetine may increase the serotonergic activities of Olanzapine. Olanzapine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorphenamine. The therapeutic efficacy of Liraglutide can be decreased when used in combination with Olanzapine. Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydrocodeine. Olanzapine may increase the QTc-prolonging activities of Quinidine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Thiothixene. The serum concentration of Indinavir can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Triazolam is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Diphenhydramine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Risperidone. Minocycline may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The risk or severity of adverse effects can be increased when Methylergometrine is combined with Olanzapine. Hydracarbazine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Deramciclane. The serum concentration of Thioridazine can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Brompheniramine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclobenzaprine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pipamperone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Alphacetylmethadol.